{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"All adverse events are tracked during the course of the trial. Adverse events with a grade of 3-4 will be tracked and recorded.","groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.\n\nBendamustine hydrochloride: Given IV\n\nBortezomib: Given SC\n\nDexamethasone: Given PO","id":"OG000","title":"Bendamustine, Bortezomib, Dexamethasone (Standard)"}],"paramType":"NUMBER","populationDescription":"4 were not evaluable - (1 didn't get any therapy on study, 1 received only first cycle and 2 developed medical issues that took them off study during the first cycle)","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Incidence of Grade 3-4 Adverse Events From the Combination of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone Based on the Common Terminology Criteria Version 4.0","type":"SECONDARY","unitOfMeasure":"Adverse Events"}